Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp453 | Osteoporosis: treatment | ECTS2013

Factors influencing levels of bone resorption during denosumab dosing

Eastell Richard , Siris Ethel , Roux Christian , Black Dennis M. , Franchimont Nathalie , Jang Graham , Daizadeh Nadia , Wagman Rachel B. , Austin Matt

Denosumab treatment is associated with low fracture incidence, sustained BMD increases, and reduced sCTX. The decrease in median sCTX is at the quantifiable limit (0.049 ng/ml) one month post-dose, remains low, and attenuates at the end of the 6-month dosing interval. Using 7 years of data from the FREEDOM study and its extension, we characterized changes in sCTX over time and the influencing factors. In the bone turnover marker and pharmacokinetic substudies, serum was collec...

ba0003lb2 | (1) | ECTS2014

Bisphosphonates for osteoporosis and risk of breast cancer: misleading results from observational studies

Cummings Steven R , Hue Trisha , Cauley Jane A , Bauer Doug C , Ensrud Kristine E , Barrett-Connor Elizabeth , Black Dennis M

Purpose: To test whether bisphosphonates for osteoporosis reduce the risk of breast cancer.Background: Observational studies and meta-analyses find that women taking bisphosphonates have about a 1/3rd reduction in risk of breast cancer as soon as 1 year of treatment. This is plausible because bisphosphonates have in vitro anti-tumor activity and high doses of zoledronate reduce recurrence in women with breast cancer. However, observational studi...